Status:
COMPLETED
Impact of Prior SGLT2 Inhibitors Use on the Development and Progression of Sepsis-Associated Acute Kidney Injury
Lead Sponsor:
University of Jazan
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
18-75 years
Brief Summary
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
Detailed Description
The primary objective of this study is to investigate whether using SGLT2i may be associated with decreased incidence of sepsis-induced AKI or not.
Eligibility Criteria
Inclusion
- All adult (≥ 18 year) patients who were admitted to ICU with sepsis syndromes (sepsis or septic shock), according to sepsis-3 definition.
Exclusion
- Missing data
- Renal transplant or tumor
- Solitary kidney
- Established CKD
- Obstructive uropathy
- Renal artery stenosis
- Pregnancy
Key Trial Info
Start Date :
April 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
664 Patients enrolled
Trial Details
Trial ID
NCT06902493
Start Date
April 1 2024
End Date
March 1 2025
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Fahd Central Hospital
Al ‘Usaylah, Saudi Arabia